Alzinova AB (publ)

Stockholm Stock Exchange ALZ.ST

Alzinova AB (publ) Debt to Equity Ratio for the year ending December 31, 2023

Alzinova AB (publ) Debt to Equity Ratio is NA for the year ending December 31, 2023. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Stockholm Stock Exchange: ALZ.ST

Alzinova AB (publ)

CEO	Dr. Tord Labuda M.Sc., Ph.D.
IPO Date	Nov. 25, 2015
Location	Sweden
Headquarters	Pepparedsleden 1
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Pharmaceuticals Vaccines

Description

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Key trends

Past 5 years